INVO Fertility, Inc. (IVF) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.
Analysis Summary
INVO Fertility, Inc. reported revenue of $6.8M in the most recent fiscal year, growing at a 5-year CAGR of 45.8%.
Balance sheet quality for IVF: current ratio of 0.3, net debt of $1.3M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Price
| Price | $0.93 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Financial Health
| Piotroski F-Score | 5 |
| Altman Z-Score | -2.01 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| IVF | INVO Fertility, Inc. | $2M | |||
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 28.37 | 4.41 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $65.3B | 17.84 | 2.62 | 14.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -34.73% |
| 3 months | -37.77% |
| Year-to-date | -75.18% |
| 1 year | -97.37% |
| 3 years | -99.93% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $84.40 |
| 52-week Low | $0.90 |
| Avg Volume (90d) | 3.2M |
Related companies: AVGR · AXDX · CMAX · CUTR · NBSE · ONCSQ · ONCT
Explore sector: Healthcare · Medical - Devices
More sections of IVF: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks